Free sugar linked to higher cardiovascular disease
A UK Biobank study suggests that higher intake of free sugars is associated with a higher risk to develop cardiovascular disease, UK researchers report in BMC Medicine.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Expansion of the Munich science line has started
The extension, which was celebrated with an official groundbreaking ceremony, will connect the IZB campus in Martinsried to the Munich subway system.
AMsilk scaling up through Evonik collaboration
Fermatation expert Evonik SE has entered into an agreement with the German recombinant silk producer AMSilk to produce industrial quantities of innovative, sustainable silk proteins.
HOOKIPA bags US$10m cancer milestone
HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.
Cydar Medical Ltd raises €10.5m in Series A financing
Cambridge-based endovascular surgical AI specialist Cydar Medical has completed a €10.5m (£9.3m) Series A funding round led by Pembroke Venture Capital Trust
Evonetix extends Series B financing to US$54m
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
TWB, an original model supporting the bioeconomy
Toulouse White Biotech (TWB) is a good example to how scaling and collaboration through production partnerships can help the industrial biotech sector to satisfy the urgent need to speed up and scale sustainable processes for industrial production.
Germany’s Curevac offers common shares
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market
Both the US Skokie and European Rankweil sites address customer needs in early-phase drug development
Chong Kun Dang Pharm licences Synaffix ADC platform
South Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BV’s propietary ADC platform.